CAR-T Warning Refinements Coming Soon From US FDA

 
• By Michael McCaughan
  
Peter Marks said the warning about secondary malignancy in CAR-T therapies soon will be revised. (Shutterstock)

More from Cell & Gene Therapies

More from Drug Safety